

=> d his

(FILE 'HOME' ENTERED AT 14:00:45 ON 06 DEC 2004)

FILE 'REGISTRY' ENTERED AT 14:01:55 ON 06 DEC 2004


L1 STRUCTURE UPLOADED
L2 8 S L1
L3 180 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:03:32 ON 06 DEC 2004

L4 4 S L3

=> d que 14 stat

L1 STR



G1 O,S,N

G2 [01].[02].[03]

Structure attributes must be viewed using STN Express query preparation.

L3 180 SEA FILE=REGISTRY SSS FUL L1

L4 4 SEA FILE=CAPLUS ABB=ON PLU=ON L3

=> d 1-4 bib abs hitstr

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 AN 2004:467892 CAPLUS
 DN 141:38606
 TI Pyrazoloquinolines and analogs with CD80 antagonist immunomodulating activity, and their preparation, pharmaceutical compositions, and use
 IN Matthews, Ian Richard; Coulter, Thomas Stephen; Ghiron, Chiara; Brennan, Chris James; Uddin, Muhammed Kamal; Pettersson, Lars Olof Goeran; Da Graca Thirge, Dorte; Huxley, Philip
 PA Active Biotech AB, Swed.
 SO PCT Int. Appl., 55 pp.
 CODEN: PDXD2
 DT Patent
 LA English
 FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004/048378	A1	2004/0610	WO 2003-SE1805	2003/1121
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, CZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FL, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MY, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW			
RM:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZH, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004/116461	A1	2004/0617	US 2003-717519	2003/1121
PRAI SE 2002-3471	A	2002/1122		
US 2002-428240P	P	2002/1122		
US 2003-1299	A	2003/0506		
SE 2003-1851	A	2003/0625		
US 2003-482122P	P	2003/0625		
OS HARPAT 141:38606				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to novel heterocyclic compds., to methods for their preparation, to compns. containing them, and to methods and use for clin. treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosus, and psoriasis. More particularly, the invention relates to novel heterocyclic compds. 1, which are CD80 antagonists capable of inhibiting the interactions between CD80

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 (morpholin-4-yl)pyridine-3-carboxamide 702704-41-4P, Methyl N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]oxamate 702704-42-5P, Ethyl N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]carbamate 702704-43-6P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-1-phenyl-5-propylpyrazole-4-carboxamide 702704-44-7P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-5-phenylloxazole-4-carboxamide 702704-45-8P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]acetamide 702704-46-9P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-ethylhexanamide 702704-47-0P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-ethylbutanamide 702704-48-1P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-cyclopropylacetamide 702704-49-2P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-1-acetylperidide-4-carboxamide 702704-50-3P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2,6-dichlorobenzenesulfonamide 702704-51-4P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-acetoxy-2-methylpropanamide 702704-52-7P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-10-methoxy-10-oxodecanamide 702704-53-8P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-1-sobutanamide 702704-54-9P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-(2-methoxyethoxy)acetamide 702704-55-0P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-methoxyacetamide 702704-56-1P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-1-oxazole-5-carboxamide 702704-57-2P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-4-(trimethylammonio)butanamide 702704-58-3P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-4-(dimethylamino)butanamide 702704-59-4P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-[[3-(methoxyphenylamino)propyl]amino]acetamide 702704-60-7P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-[[4-(dimethylamino)phenyl]methyl]amino]acetamide 702704-61-8P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-[[1,2,2,6,6-pentamethylpiperidin-4-yl]amino]acetamide 702704-62-9P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-(4-cyclohexylpiperazin-1-yl)acetamide 702704-63-0P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-[[3-(2-oxopyrrolidin-1-yl)propyl]amino]acetamide 702704-64-1P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-[[2-(pyridin-2-yl)ethyl]amino]acetamide 702704-65-2P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-[[2-oxoazepan-3-yl]amino]acetamide 702704-66-3P, (S)-N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-amino-5-methoxy-5-oxopentanamide 702704-67-4P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-[[2-(1-methylpyrrolidin-2-yl)ethyl]amino]acetamide 702704-68-5P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-[[3-(1H-imidazol-1-yl)propyl]amino]acetamide 702704-69-6P.

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 and CD80. In formula 1, R1 and R3 independently represent H, F, Cl, Br, NO2, CN, C1-C6 alkyl optionally substituted by F or Cl, or C1-C6 alkoxy optionally substituted by F; R2 represents H, or optionally substituted C1-C6 alkyl, C3-C7 cycloalkyl, or optionally substituted Ph; Y represents O, S, N-oxide, or N(R5), wherein R5 represents H or C1-C6 alkyl; X represents a bond or a divalent C1-C6 alkylene radical; R4 represents -C(O)NR6R7, -NR7C(O)R6, -NR7C(O)OR6, -NHC(O)NR6, or -NHC(S)NR6, wherein R6 represents H, or a radical of formula -(Alk)nb-Q wherein b = 0-1 and Alk is an optionally substituted divalent straight chain or branched C1-C12 alkylene, C2-C12 alkenylene or C2-C12 alkynylene radical which may be interrupted by one or more non-adjacent -O-, -S- or -N(R8)- radicals wherein R8 represents H or C1-C4 alkyl, C3-C4 alkenyl, C3-C4 alkynyl, or C3-C6 cycloalkyl, and Q represents H, CF3, OH, SH, NR8R8 wherein each R8 may be the same or different, an ester group, or an optionally substituted Ph, C3-C7 cycloalkyl, C5-C7 cycloalkenyl or heterocyclic ring having from 5 to 8 ring atoms; and R7 represents H or C1-C6 alkyl; or when taken together with the atom or atoms to which they are attached, R6 and R7 form an optionally substituted heterocyclic ring having from 5 to 8 ring atoms. Approx. 170 example compds. and several intermediates were prep'd. For instance, invention compd. II (claimed individually) was prep'd. in 5 steps: (1) cyclocondensation of 3-cyclopropyl-3-oxopropionic acid Me ester with Et 2-aminobenzoate to give a quinolone deriv., (2) conversion of the quinolone ester to a chloroquinoline ester with POCl3, (3) cyclocondensation of the latter with 4-hydrazinobenzoyl acid to form the pyrazole ring, (4) conversion of the free acid group to an acid chloride, and (5) amidation with H2N(CH2)3NMe2. In a cell-free, FRET-based, homogeneous time-resolved fluorescence (HTRF) assay, used to det. inhibition of CD80-CD28 interaction, II had EC50 < 1 μM.
 II 77779-57-9P, 4-(3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide 702704-10-1P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-methylbutyramide 702704-31-2P, 2-Methylpentanoic acid [4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]amide 702704-32-3P, 1-Methyl-1H-pyrrole-2-carboxylic acid [4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]amide 702704-33-4P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-3-methylbutyramide 702704-34-5P, 2-Propylpentanoic acid [4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]amide 702704-35-6P, 5-[[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]carbamyl]pentanoic acid methyl ester 702704-36-7P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2,2-dimethylpropionamide 702704-37-8P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-(phenylmethoxy)acetamide 702704-38-9P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-chloroacetamide 702704-39-0P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-furancarboxamide 702704-40-1P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-6-


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-[[2-(diisopropylamino)ethyl]amino]acetamide 702704-70-9P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-piperidinylacetamide 702704-71-0P, N-[4-(3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-amino propanamide 702704-72-1P, N-[4-(3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-methylpentanamide 702704-73-2P, N-[4-(3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-1-sobutanamide 702704-74-3P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-amino propanamide 702704-75-4P, N-[4-(3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-methylbutanamide 702704-76-5P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-[[4-(4-fluorophenyl)methyl]piperazin-1-yl]acetamide 702704-77-6P, N-[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]-2-(N-methylbenzylamino)acetamide 702704-78-7P, 3-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)-N-(3-methoxypropyl)benzamide 702704-79-8P, N-Ethyl-3-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide 702704-80-1P, N-Benzyl-3-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide 702704-81-2P, N-Methyl-N-[3-(dimethylamino)propyl]-3-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide 702704-82-3P, N-[3-(Dimethylamino)propyl]-3-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide 702704-83-4P, trans-N-[4-(Aminocyclohexyl)-3-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide 702704-84-5P, N-[3-(Pyrrolidin-1-yl)propyl]-3-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide 702704-85-6P, N-[4-(Pyrrolidin-1-yl)butyl]-3-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide 702704-86-7P, N-[4-(Dimethylamino)butyl]-3-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide 702704-87-8P, N-(2-Methoxyethyl)-3-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide 702704-88-9P, N,N-Diethyl-3-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide 702704-89-0P, N-[(Methoxycarbonyl)methyl]-3-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide 702704-90-1P, N-Propargyl-3-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide 702704-91-4P, N-Benzyl-N-methyl-3-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide 702704-92-5P, Ethyl 1-[[3-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]carbamyl]piperidine-4-carboxylate 702704-93-6P, N-[3-(Dimethylamino)propyl]-4-(4-cyclopropyl-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide 702704-94-7P, N-[3-(Dimethylamino)propyl]-4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide hydrochloride 702704-95-8P, 1-[[4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)phenyl]carbamyl]piperidine 702704-96-9P, N-Benzyl-4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide 702704-97-0P, N-Benzyl-N-methyl-4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide 702704-98-1P, N-(2-Methoxyethyl)-4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-c]quinolin-2-yl)benzamide 702704-99-2P, N-[2-(Dimethylamino)ethyl]-4-(6-fluoro-3-oxo-3,5-dihydroprazol[4,3-

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 c]quinolin-2-yl)benzamide 702705-00-0P, N-
 [(Methoxycarbonyl)methyl]-4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-
 c]quinolin-2-yl)benzamide 702705-01-9P, N-(3-Methoxypropyl)-4-(6-
 fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide
 702705-02-0P, N-[3-(Dimethylamino)propyl]-4-(6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-03-1P,
 N-[2-(Cyclohex-1-enyl)ethyl]-4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-
 c]quinolin-2-yl)benzamide 702705-04-2P, N-(Cyclohexylmethyl)-4-
 (6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide
 702705-05-3P, N-Ethyl-4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-
 c]quinolin-2-yl)benzamide 702705-06-4P, N,N-Diethyl-4-(6-fluoro-
 3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide
 702705-07-5P, N-(trans-4-Aminocyclohexyl)-4-(6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-08-6P,
 N-[3-(Dimethylamino)propyl]-N-methyl-4-(6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-09-7P,
 N-(4-(Dimethylamino)butyl)-4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-
 c]quinolin-2-yl)benzamide 702705-10-0P, N-[4-(Pyrrolidin-1-
 yl)butyl]-4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-
 yl)benzamide 702705-11-1P, N-[3-(Pyrrolidin-1-yl)propyl]-4-(6-
 fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide
 702705-12-2P, N-[2-[4-(Phenylmethyl)piperazin-1-yl]ethyl]-4-(6-
 fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide
 702705-13-3P, N-[6-(Dimethylamino)hexyl]-4-(6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-14-4P,
 N-[3-(Dimethylamino)propyl]-4-(3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-
 yl)benzamide 702705-15-5P, N-[6-(Dimethylamino)hexyl]-4-(3-oxo-
 3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-16-6P,
 N-(4-(Diethylamino)butyl)-4-(3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-
 yl)benzamide 702705-17-7P, N-[3-(Dimethylamino)propyl]-N-methyl-
 4-(3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide
 702705-18-0P, N-[3-(Dimethylamino)propyl]-4-(6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)-2-chlorobenzamide
 702705-19-9P, N-[3-(Pyrrolidin-1-yl)propyl]-4-(3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-20-2P,
 N-[3-[4-[(2-Chloro-6-fluorophenyl)methyl]piperazin-1-yl]propyl]-4-(3-oxo-
 3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-21-3P,
 N-[3-(4-Methylpiperazin-1-yl)propyl]-4-(3-oxo-3,5-dihydropyrazolo[4,3-
 c]quinolin-2-yl)benzamide 702705-22-4P, N-[2-[4-
 (Phenylmethyl)piperazin-1-yl]ethyl]-4-(3-oxo-3,5-dihydropyrazolo[4,3-
 c]quinolin-2-yl)benzamide 702705-23-5P, N-[3-[4-[(2-Chloro-6-
 fluorophenyl)methyl]piperazin-1-yl]propyl]-4-(6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-24-6P,
 N-(4-(Diethylamino)-1-methylbutyl)-4-(6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-25-7P,
 N-[3-(4-Methylpiperazin-1-yl)propyl]-4-(6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-26-0P,
 N-(4-(Pyrrolidin-1-yl)butyl)-4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-
 c]quinolin-2-yl)benzamide 702705-27-9P,


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 c]quinolin-2-yl)-3-chlorobenzamide 702705-27-9P,
 N-[3-(4-Methylpiperazin-1-yl)propyl]-4-(6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)-2-chlorobenzamide
 702705-28-0P, N-[4-(Diethylamino)butyl]-4-(6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)-2-chlorobenzamide
 702705-29-1P, N-[3-(Dimethylamino)propyl]-4-(6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)-3-chlorobenzamide
 702705-30-4P, N-[4-(Pyrrolidin-1-yl)butyl]-4-(4-cyclopropyl-3-oxo-
 3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-31-5P,
 1-[[4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-
 yl)]phenyl]carbonyl]-4-(4-chlorobenzyl)piperazine 702705-32-6P,
 N-[3-(Methylphenylamino)propyl]-4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-
 c]quinolin-2-yl)benzamide 702705-33-7P, N-[2-
 (Diisopropylamino)ethyl]-4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-
 c]quinolin-2-yl)benzamide 702705-34-0P, N-[3-(2-Methylpiperidin-
 1-yl)propyl]-4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)-2-
 chlorobenzamide 702705-35-9P, N-[4-(Dimethylamino)benzyl]-4-(6-
 fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide
 702705-36-0P, N-[4-(Dimethylamino)butyl]-4-(6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)-2-chlorobenzamide
 702705-37-1P, 1-[[4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-
 c]quinolin-2-yl)]phenyl]carbonyl]-4-methylpiperazine 702705-38-2P
 N-[3-(2-Methylpiperidin-1-yl)propyl]-4-(6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-39-3P,
 N-[2-(Morpholin-4-yl)ethyl]-4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-
 c]quinolin-2-yl)benzamide 702705-40-6P, N-[1-(1-Ethylpyrrolidin-2-
 yl)methyl]-4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-
 yl)benzamide 702705-41-7P, N-(1,2,2,6,6-Pentamethylpiperidin-4-
 yl)-4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide
 702705-42-0P, N-(1-Benzylpiperidin-4-yl)-4-(6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-43-9P,
 N-[2,2-Dimethyl-3-(dimethylamino)propyl]-4-(6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-44-0P,
 N-(2,2,6,6-Tetramethylpiperidin-4-yl)-4-(6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-45-1P,
 N-(2-(Pyrrolidin-3-yl)ethyl)-4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-
 c]quinolin-2-yl)benzamide 702705-46-2P, N-[2-(Ethylthio)ethyl]-4-
 (6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide
 702705-47-3P, N-[3-(2-Oxopyrrolidin-1-yl)propyl]-4-(6-fluoro-3-oxo-
 3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-48-4P,
 N-[3-(1-imidazol-1-yl)propyl]-4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-
 c]quinolin-2-yl)benzamide 702705-49-5P, N-(2-Oxazepan-3-yl)-4-
 (6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide
 702705-50-0P, N-(4-(Diethylamino)butyl)-4-(6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-51-9P,
 N-(1-Benzyl-4-piperidinyl)-4-(4-cyclopropyl-6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-52-0P,
 N-(1,2,2,6,6-Pentamethylpiperidin-4-yl)-4-(4-cyclopropyl-6-fluoro-3-oxo-
 3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-53-1P,

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-53-1P,
 N-[2-(Pyrrolidin-2-yl)ethyl]-4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-
 c]quinolin-2-yl)benzamide 702705-54-2P, N-[3-(Methylthio)propyl]-
 4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide
 702705-55-3P, N-(1,2,2,6,6-Pentamethylpiperidin-4-yl)-4-(4-
 cyclopropyl-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide
 702705-56-4P, N-[4-(Pyrrolidin-1-yl)butyl]-4-(4-cyclopropyl-6-
 fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide
 702705-57-5P, endo-N-(8-Methyl-8-azabicyclo[3,2,1]oct-3-yl)-4-(6-
 fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide
 702705-58-6P, N-[3-(Dimethylamino)propyl]-4-(4-cyclopropyl-6-
 fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide
 702705-59-7P, N-(2,2,6,6-Tetramethylpiperidin-4-yl)-4-(4-
 cyclopropyl-6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-
 yl)benzamide 702705-60-0P, endo-N-(8-Methyl-8-
 azabicyclo[3,2,1]oct-3-yl)-4-(4-cyclopropyl-6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-61-1P,
 N-[4-(Diethylamino)butyl]-4-(4-cyclopropyl-6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-62-2P,
 N-[1-(tert-Butoxycarbonyl)piperidin-4-yl]-4-(4-cyclopropyl-6-fluoro-3-oxo-
 3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-63-3P,
 N-[3-[4-[(2-Chloro-6-fluorophenyl)methyl]piperazin-1-yl]propyl]-4-(4-
 cyclopropyl-6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-
 yl)benzamide 702705-64-4P, N-[2-(Pyrrolidin-3-yl)ethyl]-4-(4-
 cyclopropyl-6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-
 yl)benzamide 702705-65-5P, N-[2-(Pyrrolidin-3-yl)ethyl]-4-(4-
 cyclopropyl-6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-
 yl)benzamide 702705-66-6P, N-[2,2-Dimethyl-3-
 (dimethylamino)propyl]-4-(4-cyclopropyl-6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-67-7P,
 N-[3-(Pyrrolidin-1-yl)propyl]-4-(4-cyclopropyl-6-fluoro-3-oxo-3,5-
 dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-68-0P
 N-[3-[4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-
 yl)]phenyl]ureido]acetic acid ethyl ester 702705-69-9P,
 2-[3-[4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-
 yl)]phenyl]ureido]propanoic acid ethyl ester 702705-70-2P
 702705-71-3P 702705-72-4P 702705-73-5P
 702705-74-6P 702705-75-7P 702705-76-0P
 702705-77-9P 702705-78-0P 702705-79-1P
 702705-80-4P 702705-81-5P 702705-82-6P
 702705-83-7P 702705-84-0P 702705-85-9P
 702705-86-0P 702705-87-1P 702705-88-2P
 702705-89-3P 702705-90-6P, N-[3-(Dimethylamino)propyl]-4-
 [3-oxo-3H-thiophene[4,3-c]pyrazol-2-yl]benzamide 702705-91-7P
 N-[3-(Cyclohexylamino)propyl]-4-[3-oxo-3H-thiophene[4,3-c]pyrazol-2-
 yl]benzamide 702705-92-0P, N-[4-(Pyrrolidin-1-yl)butyl]-4-(3-oxo-
 3H-thiophene[4,3-c]pyrazol-2-yl)benzamide 702705-93-9P,
 4-(3-oxo-3H-thiophene[4,3-c]pyrazol-2-yl)-N-(1,2,2,6,6-
 pentamethylpiperidin-4-yl)benzamide 702705-94-0P,
 N-[3-(Dimethylamino)propyl]-4-(6-fluoro-3-oxo-3H-thiophene[4,3-
 c]pyrazol-2-yl)benzamide 702705-95-1P, N-[3-
 (Cyclohexylamino)propyl]-4-(6-fluoro-3-oxo-3H-thiophene[4,3-c]pyrazol-2-
 yl)benzamide 702705-96-2P,


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 yl)benzamide 702705-96-2P, N-[4-(Pyrrolidin-1-yl)butyl]-4-(6-
 fluoro-3-oxo-3H-thiophene[4,3-c]pyrazol-2-yl)benzamide
 702705-97-3P, 2-[3-[4-(6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-
 c]quinolin-2-yl)]phenyl]ureido]-3-phenylpropanoic acid ethyl ester
 702705-98-4P, 4-(6-fluoro-3-oxo-3H-thiophene[4,3-c]pyrazol-2-
 yl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BTOL (Biological study); PREP (Preparation); USES
 (Uses)
 (drug candidate: prepn. of pyrazoloquinolines and analogs as CD80
 antagonists and immunomodulators)
 RN 77779-57-8 CAPLUS
 CN Benzamide, 4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9C1)
 (CA INDEX NAME)



RN 702704-30-1 CAPLUS
 CN Butanamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-
 yl)]phenyl]-2-methyl- (9C1) (CA INDEX NAME)




RN 702704-31-2 CAPLUS
 CN Pentanamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-
 yl)]phenyl]-2-methyl- (9C1) (CA INDEX NAME)




RN 702704-32-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-
 c]quinolin-2-yl)]phenyl]-1-methyl- (9C1) (CA INDEX NAME)


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 702704-33-4 CAPLUS
 CN Butanamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 702704-34-5 CAPLUS
 CN Pentanamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 702704-35-6 CAPLUS
 CN Hexanoic acid, 6-[[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]amino]-6-oxo-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 702704-39-0 CAPLUS
 CN 2-Furancarboxamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 702704-40-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 702704-41-4 CAPLUS
 CN Acetic acid, [[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]amino]oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 702704-42-5 CAPLUS
 CN Carbamic acid, [4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702704-36-7 CAPLUS
 CN Propanamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 702704-37-8 CAPLUS
 CN Acetamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 702704-38-9 CAPLUS
 CN Acetamide, 2-chloro-N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 702704-43-6 CAPLUS
 CN 1H-Pyrazole-4-carboxamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-1-phenyl-5-propyl- (9CI) (CA INDEX NAME)




RN 702704-44-7 CAPLUS
 CN 4-Oxazecarboxamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 702704-45-8 CAPLUS
 CN Hexanamide, 2-ethyl-N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 702704-46-9 CAPLUS
 CN Hexanamide, 2-ethyl-N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 702704-47-0 CAPLUS

CN Butanamide, 2-ethyl-N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 702704-48-1 CAPLUS

CN Cyclopentaneacetamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 702704-49-2 CAPLUS

CN 4-Piperidinecarboxamide, 1-acetyl-N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 702704-50-5 CAPLUS


CN Benzeneacetamide, 2,6-dichloro-N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 702704-54-9 CAPLUS

CN Acetamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)




RN 702704-55-0 CAPLUS

CN Acetamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 702704-56-1 CAPLUS

CN 5-Isoxazolecarboxamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 702704-57-2 CAPLUS

CN 1-Butanaminium, 4-[[[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]amino]-N,N,N-trimethyl-4-oxo- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702704-51-6 CAPLUS

CN Propanamide, 2-(acetyloxy)-N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 702704-52-7 CAPLUS

CN Decanoic acid, 10-[[[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]amino]-10-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 702704-53-8 CAPLUS


CN Propanamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 702704-58-3 CAPLUS

CN Butanamide, 4-(dimethylamino)-N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 702704-59-4 CAPLUS

CN Acetamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2-[[3-(methylphenylamino)propyl]amino]- (9CI) (CA INDEX NAME)



RN 702704-60-7 CAPLUS

CN Acetamide, 2-[[[4-(dimethylamino)phenyl]methyl]amino]-N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 702704-61-8 CAPLUS


CN Acetamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2-[[1,2,2,6,6-pentamethyl-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702704-62-9 CAPLUS
 CN 1-Piperazineacetamide, 4-cycloheptyl-N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 702704-63-0 CAPLUS
 CN Acetamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]- (9CI) (CA INDEX NAME)




RN 702704-64-1 CAPLUS
 CN Acetamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2-[[2-(2-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN Acetamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2-[[3-(1H-imidazol-1-yl)propyl]amino]- (9CI) (CA INDEX NAME)




RN 702704-69-6 CAPLUS
 CN Acetamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2-[[2-bis(1-methylethyl)amino]ethyl]amino]-N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 702704-70-9 CAPLUS
 CN 1-Piperidineacetamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 702704-71-0 CAPLUS
 CN Propanamide, 2-amino-N-[4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 702704-65-2 CAPLUS
 CN Acetamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2-[[hexahydro-2-oxo-1H-azepin-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 702704-66-3 CAPLUS
 CN Pentanoic acid, 4-amino-5-[[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]amino]-5-oxo-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702704-67-4 CAPLUS
 CN Acetamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 702704-68-5 CAPLUS

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 702704-72-1 CAPLUS
 CN Pentanamide, N-[4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 702704-73-2 CAPLUS
 CN Propanamide, N-[4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 702704-74-3 CAPLUS
 CN Propanamide, 2-amino-N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 702704-75-4 CAPLUS
 CN Butanamide, N-[4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702704-76-5 CAPLUS
 CN 1-Piperazineacetamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-4-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 702704-77-6 CAPLUS
 CN Acetamide, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-2-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 702704-78-7 CAPLUS
 CN Benzamide, 3-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702704-83-4 CAPLUS
 CN Benzamide, N-(trans-4-aminocyclohexyl)-3-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 702704-84-5 CAPLUS
 CN Benzamide, 3-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 702704-85-6 CAPLUS
 CN Benzamide, 3-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)




RN 702704-86-7 CAPLUS
 CN Benzamide, N-[4-(dimethylamino)butyl]-3-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 702704-79-8 CAPLUS
 CN Benzamide, N-ethyl-3-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)



RN 702704-80-1 CAPLUS
 CN Benzamide, 3-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 702704-81-2 CAPLUS
 CN Benzamide, N-[3-(dimethylamino)propyl]-3-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-methyl- (9CI) (CA INDEX NAME)




RN 702704-82-3 CAPLUS
 CN Benzamide, N-[3-(dimethylamino)propyl]-3-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702704-87-8 CAPLUS
 CN Benzamide, N-[3-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 702704-88-9 CAPLUS
 CN Benzamide, N,N-diethyl-3-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702704-89-0 CAPLUS
 CN Glycine, N-[3-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)benzoyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 702704-90-3 CAPLUS
 CN Benzamide, 3-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-2-propenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 702704-91-4 CAPLUS
 CN Benzamide, 3-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 702704-92-5 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[3-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 702704-93-6 CAPLUS
 CN Benzamide, 4-(4-cyclopropyl-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-(3-(dimethylamino)propyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702704-97-0 CAPLUS
 CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 702704-98-1 CAPLUS
 CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 702704-99-2 CAPLUS
 CN Benzamide, N-[2-(dimethylamino)ethyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702705-00-8 CAPLUS
 CN Glycine, N-(4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)benzoyl)-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702704-94-7 CAPLUS
 CN Benzamide, N-[3-(dimethylamino)propyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 702704-95-8 CAPLUS
 CN Piperidine, 1-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)benzoyl]- (9CI) (CA INDEX NAME)




RN 702704-96-9 CAPLUS
 CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702705-01-9 CAPLUS
 CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)



RN 702705-02-0 CAPLUS
 CN Benzamide, N-[3-(dimethylamino)propyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702705-03-1 CAPLUS
 CN Benzamide, N-[2-(1-cyclohexen-1-yl)ethyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702705-04-2 CAPLUS
 CN Benzamide, N-(cyclohexylmethyl)-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 702705-05-3 CAPLUS
 CN Benzamide, N-ethyl-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702705-06-4 CAPLUS
 CN Benzamide, N,N-diethyl-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702705-07-5 CAPLUS
 CN Benzamide, N-(trans-4-aminocyclohexyl)-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702705-11-1 CAPLUS
 CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 702705-12-2 CAPLUS
 CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 702705-13-3 CAPLUS
 CN Benzamide, N-[6-(dimethylamino)hexyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702705-14-4 CAPLUS
 CN Benzamide, 2-chloro-N-[3-(dimethylamino)propyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 702705-08-6 CAPLUS
 CN Benzamide, N-[3-(dimethylamino)propyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-methyl- (9CI) (CA INDEX NAME)




RN 702705-09-7 CAPLUS
 CN Benzamide, N-[4-(dimethylamino)butyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702705-10-0 CAPLUS
 CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702705-15-5 CAPLUS
 CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[6-(dimethylamino)hexyl]- (9CI) (CA INDEX NAME)



RN 702705-16-6 CAPLUS
 CN Benzamide, N-[4-(diethylamino)butyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702705-17-7 CAPLUS
 CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(dimethylamino)propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 702705-18-8 CAPLUS
 CN Benzamide, 2-chloro-N-[3-(dimethylamino)propyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702705-19-9 CAPLUS
 CN Benzamide, 4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 702705-20-2 CAPLUS
 CN Benzamide, N-[3-[4-[(2-chloro-6-fluorophenyl)methyl]-1-piperazinyl]propyl]-4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702705-21-3 CAPLUS
 CN Benzamide, 4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702705-26-8 CAPLUS
 CN Benzamide, 3-chloro-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)



RN 702705-27-9 CAPLUS
 CN Benzamide, 2-chloro-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




RN 702705-28-0 CAPLUS
 CN Benzamide, 2-chloro-N-[4-(diethylamino)butyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702705-29-1 CAPLUS
 CN Benzamide, 3-chloro-N-[3-(dimethylamino)propyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 702705-22-4 CAPLUS
 CN Benzamide, 4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 702705-23-5 CAPLUS
 CN Benzamide, N-[3-[4-[(2-chloro-6-fluorophenyl)methyl]-1-piperazinyl]propyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702705-24-6 CAPLUS
 CN Benzamide, N-[4-(diethylamino)-1-methylbutyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702705-25-7 CAPLUS
 CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702705-30-4 CAPLUS
 CN Benzamide, 4-(4-cyclopropyl-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)



RN 702705-31-5 CAPLUS
 CN Piperazine, 1-[(4-chlorophenyl)methyl]-4-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)benzoyl]- (9CI) (CA INDEX NAME)




RN 702705-32-6 CAPLUS
 CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(methylphenylamino)propyl]- (9CI) (CA INDEX NAME)



RN 702705-33-7 CAPLUS


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CN Benzamide, N-[2-bis(1-methylethylamino)ethyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702705-34-8 CAPLUS

CN Benzamide, 2-chloro-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(2-methyl-1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 702705-35-9 CAPLUS

CN Benzamide, N-[[4-(dimethylamino)phenyl]methyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702705-36-0 CAPLUS

CN Benzamide, 2-chloro-N-[4-(dimethylamino)butyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 702705-40-6 CAPLUS

CN Benzamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702705-41-7 CAPLUS

CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 702705-42-8 CAPLUS

CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-(1-(phenylmethyl)-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 702705-43-9 CAPLUS

CN Benzamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702705-37-1 CAPLUS

CN Piperazine, 1-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)benzoyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 702705-38-2 CAPLUS

CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(2-methyl-1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 702705-39-3 CAPLUS


CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 702705-44-0 CAPLUS

CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 702705-45-1 CAPLUS

CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 702705-46-2 CAPLUS

CN Benzamide, N-[2-(ethylthio)ethyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702705-47-3 CAPLUS

CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 702705-48-4 CAPLUS
 CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 702705-49-5 CAPLUS
 CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-(hexahydro-2-oxo-1H-azepin-3-yl)- (9CI) (CA INDEX NAME)




RN 702705-50-8 CAPLUS
 CN Benzamide, N-[4-(diethylamino)butyl]-4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702705-51-9 CAPLUS
 CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 702705-55-3 CAPLUS
 CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 702705-56-4 CAPLUS
 CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-(4-(1-pyrrolidinyl)butyl)- (9CI) (CA INDEX NAME)




RN 702705-57-5 CAPLUS
 CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.




L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 702705-52-0 CAPLUS
 CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 702705-53-1 CAPLUS
 CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 702705-54-2 CAPLUS
 CN Benzamide, 4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(methylthio)propyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 702705-58-6 CAPLUS
 CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 702705-59-7 CAPLUS
 CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 702705-60-0 CAPLUS
 CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 702705-61-1 CAPLUS


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[4-(diethylamino)butyl]- (9CI) (CA INDEX NAME)




RN 702705-62-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)benzyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 702705-63-3 CAPLUS
 CN Benzamide, N-[3-{4-[(2-chloro-6-fluorophenyl)methyl]-1-piperazinyl}propyl]-4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)




RN 702705-64-4 CAPLUS
 CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702705-68-8 CAPLUS
 CN Glycine, N-[[[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 702705-69-9 CAPLUS
 CN L-Alanine, N-[[[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 702705-70-2 CAPLUS
 CN Urea, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 702705-65-5 CAPLUS
 CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 702705-66-6 CAPLUS
 CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(dimethylamino)-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)




RN 702705-67-7 CAPLUS
 CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 702705-71-3 CAPLUS
 CN Urea, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-N'-propyl- (9CI) (CA INDEX NAME)




RN 702705-72-4 CAPLUS
 CN Urea, N-(1,1-dimethylethyl)-N'-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 702705-73-5 CAPLUS
 CN Urea, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 702705-74-6 CAPLUS
 CN Thiourea, N-cyclopropyl-N'-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 702705-75-7 CAPLUS

CN Thiourea, N-cyclohexyl-N'-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 702705-76-8 CAPLUS

CN Carbamic acid, [4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 702705-77-9 CAPLUS


CN Carbamic acid, [4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 702705-78-0 CAPLUS


CN Carbamic acid, [4-(4-cyclopropyl-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702705-82-6 CAPLUS

CN Thiourea, N-(1,2-dimethylpropyl)-N'-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 702705-83-7 CAPLUS

CN Urea, N-[4-(diethylamino)butyl]-N'-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 702705-84-8 CAPLUS


CN Urea, N-[4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-N'-propyl- (9CI) (CA INDEX NAME)



RN 702705-85-9 CAPLUS


CN Thiourea, N-cyclopropyl-N'-[4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702705-79-1 CAPLUS

CN Carbamic acid, [4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-, 3-(dimethylamino)propyl ester (9CI) (CA INDEX NAME)



RN 702705-80-4 CAPLUS


CN Carbamic acid, [4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-, 1-(phenylmethyl)-4-piperidyl ester (9CI) (CA INDEX NAME)



RN 702705-81-5 CAPLUS


CN Thiourea, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-N'-pentyl- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 702705-86-0 CAPLUS


CN Urea, N-[3-(dimethylamino)propyl]-N'-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 702705-87-1 CAPLUS


CN L-Valine, N-[[[4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702705-88-2 CAPLUS


CN Urea, N-[4-(dimethylamino)butyl]-N'-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 702705-89-3 CAPLUS

CN Urea, N-[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 y1)phenyl]-N'-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)



RN 702705-90-6 CAPLUS
 CN Benzamide, N-[3-(dimethylamino)propyl]-4-(3-oxo-1-benzothio-2-pyrazol-2(3H)-yl)- (9CI) (CA INDEX NAME)




RN 702705-91-7 CAPLUS
 CN Benzamide, N-[3-(cyclohexylamino)propyl]-4-(3-oxo-1-benzothio-2-pyrazol-2(3H)-yl)- (9CI) (CA INDEX NAME)



RN 702705-92-8 CAPLUS
 CN Benzamide, 4-(3-oxo-1-benzothio-2-pyrazol-2(3H)-yl)-N-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 702705-96-2 CAPLUS
 CN Benzamide, 4-(6-fluoro-3-oxo-1-benzothio-2-pyrazol-2(3H)-yl)-N-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)




RN 702705-97-3 CAPLUS
 CN L-Phenylalanine, N-[[[4-(6-fluoro-3,5-dihydro-3-oxo-2H-pyrazol-2(3H)-yl)-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)]-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702705-98-4 CAPLUS
 CN Benzamide, 4-(6-fluoro-3-oxo-1-benzothio-2-pyrazol-2(3H)-yl)-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 702705-93-9 CAPLUS
 CN Benzamide, 4-(3-oxo-1-benzothio-2-pyrazol-2(3H)-yl)-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 702705-94-0 CAPLUS
 CN Benzamide, N-[3-(dimethylamino)propyl]-4-(6-fluoro-3-oxo-1-benzothio-2-pyrazol-2(3H)-yl)- (9CI) (CA INDEX NAME)




RN 702705-95-1 CAPLUS
 CN Benzamide, N-[3-(cyclohexylamino)propyl]-4-(6-fluoro-3-oxo-1-benzothio-2-pyrazol-2(3H)-yl)- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:42272 CAPLUS
 DN 130:106694
 TI Preparation of pyrazoloquinolines and related compounds as CD80 antagonists useful as immunomodulators
 IN Bjoerk, Per Axel; Fax, Tomas; Pettersson, Lars Olaf Goeran; Sorensen, Poul; Da Graca, Thirge Dortha
 PA Active Biotech AB, Swed.
 SO PCT Int. Appl. 40 pp.
 COEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003004495	A1	20030116	WO 2002-SE1309	20020702
W. AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZH, ZW, AM, AZ, BY, KG				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003022913	A1	20030130	US 2002-179731	20020626
US 6642249	B2	20031104		
EP 1409405	A1	20040421	EP 2002-746260	20020702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002010776	A	20040720	BR 2002-10776	20020702
NZ 530316	A	20040827	NZ 2002-530316	20020702
PRAI SE 2001-2404	A	20010704		
US 2001-302666P	P	20010705		
WO 2002-SE1309	W	20020702		
OS MARPAT 130:106694				
GI				



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 AB Title comps. [1: X = bond, (substituted) A, NHCOA, NHCOCH2CH2, CONHAA: A = alkyl; AA = amino acid residue; Y = NR4, O, S; R1 = H, halo, CF3, A, alkoxy; R2, R4 = H, A; R3 = H, halo, A, alkoxy], were prepared. Thus, 2-(3-aminophenyl)-2,5-dihydropyrazolo[4,3-c]quinolin-3-one, diglycolic anhydride, and 4-dimethylaminopyridine were stirred 3 h in DMF to give [[3-(3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)phenyl]carbonyl]methoxy]acetic acid. 2-Chloro-4-(3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzoic acid inhibited CD28-CD80 interaction with IC50 = 0.27 μ M. I are claimed for treatment of conditions which may benefit from immunomodulation, e.g. rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosus and psoriasis.
 IT 486449-37-OP 486449-39-2P 486449-40-5P 486449-41-6P 486449-42-7P 486449-43-OP 486449-44-9P 486449-56-3P 486449-57-4P
 RL: PAC (Pharmacological activity): SPN (Synthetic preparation): THU (Therapeutic use): BIOL (Biological study): PREP (Preparation): USES (Uses)
 (claimed compound; preparation of pyrazoloquinolines and related comps. as CD80 antagonists useful as immunomodulators)
 RN 486449-37-0 CAPLUS
 CN Acetic acid, [2-[[[3-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)




RN 486449-39-2 CAPLUS
 CN Butanoic acid, 4-[[[4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 486449-40-5 CAPLUS
 CN Pentanoic acid, 5-[[[4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 486449-44-9 CAPLUS
 CN Benzoic acid, 2-[[[3-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 486449-56-3 CAPLUS
 CN L-Phenylalanine, N-[4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 486449-57-4 CAPLUS
 CN Glycine, N-[4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)benzoyl]- (9CI) (CA INDEX NAME)




RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD


L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 y1)phenyl]amino]-5-oxo- (9CI) (CA INDEX NAME)



RN 486449-41-6 CAPLUS
 CN Acetic acid, [2-[[[4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



RN 486449-42-7 CAPLUS
 CN Benzeneacetic acid, alpha-[[[4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]amino]-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 486449-43-8 CAPLUS
 CN Butanoic acid, 4-[[[3-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STM

AN 1982:181283 CAPLUS

DN 96:181283

TI Pyrazoloquinolines

IN Yokoyama, Naokata

PA Ciba-Geigy Corp., USA

SD U.S., 11 pp. Cont.-in-part of U.S. Ser. No. 50,716, abandoned.

CODEN: USXXAM

DT Patent


LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4312870	A	19820126	US 1980-150398	19800516
FI 6801964	A	19801222	FI 1980-1964	19800618
FI 68827	B	19850731		
FI 68827	C	19851111		
CA 1148159	A1	19830614	CA 1980-354349	19800619
IL 60357	A1	19840531	IL 1980-60357	19800619
DK 8002648	A	19801222	DK 1980-2648	19800620
DK 160762	B	19910415		
DK 160762	C	19910923		
NO 8001866	A	19801222	NO 1980-1866	19800620
NO 153430	B	19851209		
NO 153430	C	19860319		
AU 8059455	A1	19810108	AU 1980-59455	19800620
AU 538890	B2	19840830		
ZA 8003714	A	19810624	ZA 1980-3714	19800620
HU 25561	O	19830728	HU 1980-1539	19800620
HU 183156	B	19840428		
JP 56018980	A2	19810223	JP 1980-84493	19800621
JP 03009114	B4	19910207		
DD 151754	C	19811104	DD 1980-222091	19800623
PRAI US 1979-50716	A2	19790621		

OS CASREACT 96:181283

GI



II

AB The pyrazoloquinolines I and II (R = alkyl, alkoxy, alkylthio, HO, halo).

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STM (Continued)


F3C, O2N, H2N, alkylamino, dialkylamino, cyano, H2NCO, CO2H; R1 = (un)substituted Ph, (un)substituted pyridyl; R2 = H, alkyl, hydroxyalkylamino; R3 = H, alkyl) were prepd. Thus, Et 4-chloroquinoline-3-carboxylate, prepd. in 3 steps from PhNH2 and EtOCH2C(CO2Et)2, was cyclized with p-ClC6H4NH2 to give II (R = R2 = R3 = H, R1 = p-ClC6H4). I and II were used to treat anxiety or depression in mammals (no data).

IT 77779-55-6P 77779-57-8P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)


RN 77779-55-6 CAPLUS

CN Urea, N-[4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-N'-methyl- (9CI) (CA INDEX NAME)



RN 77779-57-8 CAPLUS

CN Benzamide, 4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STM

AN 1981:407278 CAPLUS

DN 95:7278

TI Pyrazoloquinolines, pharmaceutical compositions containing them and their therapeutic use

IN Yokoyama, Naokata

PA Ciba-Geigy A.G., Switz.

SD Eur. Pat. Appl., 52 pp.

CODEN: EPXXDN


DT Patent

LA German

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 22078	A1	19810107	EP 1980-810200	19800616
EP 22078	B1	19840725		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AT 8629	E	19840815	AT 1980-810200	19800616
FI 8001964	A	19801222	FI 1980-1964	19800618
FI 68827	B	19850731		
FI 68827	C	19851111		
CA 1148159	A1	19830614	CA 1980-354349	19800619
IL 60357	A1	19840531	IL 1980-60357	19800619
DK 8002648	A	19801222	DK 1980-2648	19800620
DK 160762	B	19910415		
DK 160762	C	19910923		
NO 8001866	A	19801222	NO 1980-1866	19800620
NO 153430	B	19851209		
NO 153430	C	19860319		
AU 8059455	A1	19810108	AU 1980-59455	19800620
AU 538890	B2	19840830		
ZA 8003714	A	19810624	ZA 1980-3714	19800620
HU 25561	O	19830728	HU 1980-1539	19800620
HU 183156	B	19840428		
JP 56018980	A2	19810223	JP 1980-84493	19800621
JP 03009114	B4	19910207		
DD 151754	C	19811104	DD 1980-222091	19800623
PRAI US 1979-50716	A	19790621		
EP 1980-810200	A	19800616		

GI



II

AB Pyrazoloquinolones I and II (R = optionally substituted Ph, pyridyl; R1

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STM (Continued)


= H, optionally substituted alkyl; R2 = H, alkyl) and some related compds. were prepd. for use as tranquilizers and antidepressants (no data). Thus EtOCH2C(CO2Et)2 reacted with PhNH2 to give PhNHCH2C(CO2Et)2, which was thermally cyclized to Et 4-hydroxy-3-quinolinecarboxylate (III). Chlorination of III and reaction with 4-ClC6H4NH2 gave II (R = 4-ClC6H4, R1 = R2 = H), which was converted to II [R = 4-ClC6H4, R1 = Me, (CH2)3NHMe, R2 = H].

IT 77779-55-6P 77779-57-8P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)


RN 77779-55-6 CAPLUS

CN Urea, N-[4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-N'-methyl- (9CI) (CA INDEX NAME)



RN 77779-57-8 CAPLUS

CN Benzamide, 4-(3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (9CI) (CA INDEX NAME)



=> => d que 114 stat

L5	26	SEA FILE=CAPLUS ABB=ON PLU=ON	("MATTHEWS IAN R"/AU OR "MATTHEWS IAN RICHARD"/AU)
L6	3	SEA FILE=CAPLUS ABB=ON PLU=ON	("COULTER THOMAS S"/AU OR "COULTER THOMAS STEPHEN"/AU)
L7	13	SEA FILE=CAPLUS ABB=ON PLU=ON	"GHIRON CHIARA"/AU
L8	2	SEA FILE=CAPLUS ABB=ON PLU=ON	"BRENNAN CHRIS JAMES"/AU
L9	4	SEA FILE=CAPLUS ABB=ON PLU=ON	("UDDIN MUHAMMED K"/AU OR "UDDIN MUHAMMED KAMAL"/AU)
L10	3	SEA FILE=CAPLUS ABB=ON PLU=ON	"PETTERSSON LARS OLOF GOERAN"/A U
L11	2	SEA FILE=CAPLUS ABB=ON PLU=ON	"THRIGE DORTHE DA GRACA"/AU
L12	15	SEA FILE=CAPLUS ABB=ON PLU=ON	"HUXLEY PHILIP"/AU
L13	57	SEA FILE=CAPLUS ABB=ON PLU=ON	L5 OR L6 OR L7 OR L8 OR L9 OR L10 OR L11 OR L12
L14	3	SEA FILE=CAPLUS ABB=ON PLU=ON	L13 AND IMMUNOMOD?

=> d 1-3 bib abs

L14 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:534202 CAPLUS

DN 141:71540

TI A preparation of pyrazolo[4,3-c]quinoline derivatives, useful as immunomodulatory agents

IN Matthews, Ian Richard; Huxley, Philip; Magaraci, Filippo; Brennan, Chris James; Uddin, Muhammed Khaal; Pettersson, Lars Olof Goeran; Thrige, Dorthie Da Graca

PA Active Biotech AB, Swed.

SO PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004055014	A1	20040701	WO 2003-SE1941	20031212
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI SE 2002-3722	A	20021216		
US 2002-433580P	P	20021216		
OS MARPAT 141:71540				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of novel pyrazolo[4,3-c]quinoline derivs. of formula I [wherein: Z is carboxylic acid or ester group; X is a bond or a divalent group selected from alkylene, or NHC(O), etc.; Y is O, S, N-oxide, or NH, etc.; R1 and R3 are independently selected from H, F, Cl, NO2, or CN, etc.; R2 (un)substituted C3-cycloalkyl or phenyl] as immunomodulatory agents, useful for the treatment of rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosus, and psoriasis. The title compds. are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28. For instance, IC50 for the prepared pyrazoloquinoline derivative II was 3.4 μ M (example 7).

L14 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:467892 CAPLUS

DN 141:38606

TI Pyrazoloquinolines and analogs with CD80 antagonist immunomodulating activity, and their preparation, pharmaceutical compositions, and use

IN Matthews, Ian Richard; Coulter, Thomas Stephen; Ghiron, Chiara; Brennan, Chris James; Uddin, Muhammed Khaal; Pettersson, Lars Olof Goeran; Da Graca, Dorthie; Huxley, Philip

PA Active Biotech AB, Swed.

SO PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004048378	A1	20040610	WO 2003-SE1805	20031121
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004116461	A1	20040617	US 2003-717519	20031121
PRAI SE 2002-3471	A	20021122		
US 2002-428240P	P	20021122		
SE 2003-1299	A	20030506		
SE 2003-1851	A	20030625		
US 2003-482122P	P	20030625		
OS MARPAT 141:38606				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to novel heterocyclic compds., to methods for their preparation, to compds. containing them, and to methods and use for clin. treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosus, and psoriasis. More particularly, the invention relates to novel heterocyclic compds. I, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28. In formula I, R1 and R3 independently represent H, F, Cl, Br, NO2, CN, C1-C6 alkyl optionally substituted by F or Cl, or C1-C6 alkoxy

L14 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L14 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

optionally substituted by F; R2 represents H, or optionally substituted C1-C6 alkyl, C3-C7 cycloalkyl, or optionally substituted Ph; Y represents O, S, N-oxide, or N(R5), wherein R5 represents H or C1-C6 alkyl; X represents a bond or a divalent C1-C6 alkylene radical; R4 represents -C(O)NR6R7, -NR7C(O)R6, -NR7C(O)OR6, -NHC(O)NR6, or -NHC(S)NR6, wherein R6 represents H, or a radical of formula -(Alk)b-Q wherein b = 0-1 and Alk is an optionally substituted divalent straight chain or branched C1-C12 alkylene, C2-C12 alkenylene or C2-C12 alkynylene radical which may be interrupted by one or more non-adjacent -O-, -S- or -N(R8)- radicals wherein R8 represents H or C1-C4 alkyl, C3-C4 alkenyl, C3-C4 alkynyl, or C3-C6 cycloalkyl, and Q represents H, CF3, OH, SH, NR8R8 wherein each R8 may be the same or different, an ester group, or an optionally substituted Ph, C3-C7 cycloalkyl, C5-C7 cycloalkenyl or heterocyclic ring having from 5 to 8 ring atoms; and R7 represents H or C1-C6 alkyl; or when taken together with the atom or atoms to which they are attached, R6 and R7 form an optionally substituted heterocyclic ring having from 5 to 8 ring atoms. Approx. 170 example compds. and several intermediates were prepd. For instance, invention compd. II (claimed individually) was prepd. in 5 steps: (1) cyclocondensation of 3-cyclopropyl-3-oxopropionic acid Me ester with Et 2-aminobenzoate to give a quinolone deriv., (2) conversion of the quinolone ester to a chloroquinoline ester with POCl3, (3) cyclocondensation of the latter with 4-hydrazinobenzoic acid to form the pyrazole ring, (4) conversion of the free acid group to an acid chloride, and (5) amidation with H2N(CH2)3NMe2. In a cell-free, Eu/APC-based, homogeneous time-resolved fluorescence (HTRF) assay, used to det. inhibition of CD80-CD28 interaction, II had EC50 < 1 μ M.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS ON STN
AN 2003:42272 CAPLUS
DN 138:106694
TI Preparation of pyrazoloquinolines and related compounds as CDB0
antagonists useful as immunomodulators
IN Bjoerk, Per Axel; Fex, Tomas; Pettersson, Lars Olof Goeran;
Sorensen, Poul; Da Graca, Thirge Dorthe
PA Active Biotech Ab, Swed.
SO PCT Int. Appl. 40 pp.
CODEN: P1XXD2
DT Patent
LA English
FAM.ONT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WD 2003004495	A1	20030116	WD 2002-SE1309	20020702
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FO, GB, GD, GE, GH, GI, GR, GU, HK, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, OM, OS, PA, PE, PG, PH, PL, PT, PU, PY, RE, RO, RU, SA, SE, SG, SI, SK, SL, SM, SN, SP, SR, ST, SV, SW, SY, TD, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.				
AM, AZ, BY, KG				
RW: GH, GI, KE, LS, MW, MZ, ND, NG, NI, NO, NZ, OM, OS, PA, PE, PG, PH, PL, PT, PU, PY, RE, RO, RU, SA, SE, SG, SI, SK, SL, SM, SN, SP, SR, ST, SV, SW, SY, TD, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.				
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GU, GW, ML, MR, NE, SN, TD, TG				
US 2003022913	A1	20030130	US 2002-179731	20020626
US 6642249	B2	20031104		
EP 1409485	A1	20040421	EP 2002-746260	20020702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002010776	A	20040720	BR 2002-10776	20020702
NZ 530316	A	20040827	NZ 2002-530316	20020702
PRAI SE 2001-2404	A	20010704		
US 2001-302666P	P	20010705		
WD 2002-SE1309	W	20020702		
OS MARPAT 138:106694				
GI				



1

L14 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

AB Title compds. [I: X = bond, (substituted) A, NHCOA, NHCOCH2OCH2, CONHAA; A = alkyl; AA = amino acid residue; Y = NR4, O, S; R1 = H, halo, CF3, A, alkoxy; R2, R4 = H, A; R3 = H, halo, A, alkoxy], were prepared. Thus, 2-(3-aminophenyl)-2,5-dihydropyrazolo[4,3-c]quinolin-3-one, diglycolic anhydride, and 4-dimethylaminopyridine were stirred 3 h in DMF to give [13-(3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)phenylcarbamoyl]methoxyacetic acid. 2-Chloro-4-(3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzoic acid inhibited CD28-CD80 interaction with IC50 = 0.27 µM. I are claimed for treatment of conditions which may benefit from immunomodulation, e.g. rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosus and psoriasis.

RE.ONT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT